The researchers began by asking a deceptively simple question: does the gut microbiome of β-thalassemia mice differ from that of healthy animals in ways that could influence disease severity? To find out, they collected fecal samples from wild-type and β-thalassemia mice and subjected them to 16S rRNA sequencing, a technique that reads the genetic barcodes of bacterial communities to map their composition. The analysis revealed that P. copri stood out as a dominant pro-inflammatory bacterium in the β-thalassemia animals, prompting the team to test whether the microbe was merely a bystander or an active contributor to the disorder’s hallmark iron overload and inflammation.

To answer that question, the investigators designed a four-group experiment that separated the effects of the mutation from the effects of the bacterium. They established wild-type mice, wild-type mice given P. copri, β-thalassemia mice, and β-thalassemia mice given P. copri, delivering the bacterium by intragastric gavage, a controlled oral transplantation technique that bypasses uncertainty about natural colonization. This design allowed the researchers to observe what happens when the microbe is introduced into a system already primed by the genetic disease, and to compare it against the same introduction in healthy animals.

The results were striking. Compared with untreated β-thalassemia mice, those that received P. copri showed elevated serum levels of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin-6, alongside a decrease in the anti-inflammatory cytokine interleukin-10. At the same time, serum ferritin, a clinical marker of the body’s iron stores, rose, while ferroportin, the membrane protein responsible for exporting iron from cells into the bloodstream, fell. All of these changes reached statistical significance at p < 0.05, indicating that the bacterium was not simply adding noise to the disease picture but actively pushing the animals toward greater iron retention.

The hematological consequences were equally telling. Hemoglobin levels dropped in the P. copri-treated β-thalassemia mice, while erythropoietin and reticulocyte counts climbed. This pattern suggests that the bacterium worsened the already inefficient erythropoiesis that defines β-thalassemia, forcing the body to compensate with higher erythropoietin output and increased production of immature red blood cells. The authors note that P. copri may further aggravate ineffective erythropoiesis and erythrocyte injury in these animals, compounding the central defect of the disorder rather than merely adding a secondary complication.

To understand the molecular mechanism behind these observations, the team turned to the JAK/STAT signaling pathway, a canonical route by which interleukin-6 and related cytokines transmit inflammatory signals from the cell surface to the nucleus. Using quantitative real-time reverse transcription polymerase chain reaction and Western blotting, they measured the expression of glycoprotein 130, the co-receptor that anchors interleukin-6 signaling, along with Janus kinase 1, signal transducer and activator of transcription 3, and the phosphorylated forms of both kinases. In the β-thalassemia mice given P. copri, the expression levels of GP130, the ratio of phosphorylated to total JAK1, and the ratio of phosphorylated to total STAT3 were all upregulated, indicating that the pathway had been switched into a higher gear by the bacterial intervention.

The tissue-level evidence reinforced the molecular findings. Hematoxylin-eosin staining of colonic tissue revealed mucosal damage accompanied by inflammatory cell infiltration in the P. copri-treated β-thalassemia mice, pointing to direct intestinal injury on top of the systemic inflammation. Prussian blue staining, which highlights iron deposits as blue granules under the microscope, showed markedly aggravated iron accumulation in both the liver and the spleen of the treated animals compared with untreated β-thalassemia controls. Together, these histological observations confirmed that the bacterium’s effects were not confined to blood markers but extended to visible organ pathology.

The authors propose that P. copri exacerbates iron overload by triggering inflammatory responses and upregulating hepcidin, the liver-derived hormone that acts as the master regulator of iron homeostasis. Hepcidin binds to ferroportin and causes it to be internalized and degraded, effectively locking iron inside macrophages, hepatocytes, and enterocytes. By elevating interleukin-6, a potent inducer of hepcidin expression, and subsequently activating the JAK/STAT signaling pathway, P. copri appears to set off a cascade that suppresses iron export and traps the metal in tissues, worsening the iron burden that already plagues β-thalassemia patients.

The study’s implications reach beyond the laboratory. β-thalassemia affects populations across the Mediterranean, the Middle East, and Southeast Asia, and iron overload remains a leading cause of morbidity in these patients despite chelation therapy. If gut microbes can modulate hepcidin and iron distribution through immune signaling, then microbiome-targeted interventions, whether through dietary modification, probiotics, or antibiotics, could theoretically complement existing treatments. The finding also adds to a growing body of evidence that the intestinal microbiota is not a passive passenger in hematological disease but an active participant capable of shaping inflammation, erythropoiesis, and metal metabolism.

As with any animal study, the results require careful interpretation before they can inform clinical practice. The mouse model does not fully recapitulate the human disease, and the specific contribution of P. copri in patients with β-thalassemia remains to be established through human cohort studies. Nevertheless, the mechanistic clarity of the work, linking a specific gut bacterium to a specific signaling pathway and a specific clinical problem, offers a concrete starting point for future investigations. The research was supported by the National Natural Science Foundation of China, the Guangxi Ba Gui Scholars Special Project, and the Guangxi Medical and Health Key Discipline Construction Project, and the full article is available open access in Annals of Hematology.

Subject of Research: The role of Prevotella copri in exacerbating iron overload and chronic inflammation in β-thalassemia mice through JAK/STAT pathway activation.

Article Title: Mechanistic insights into how Prevotella copri exacerbates tissue iron retention and chronic inflammation in β-thalassemia mice via activation of the JAK/STAT signaling pathway

Article References: Li, Y., Huang, T., Chen, G., Liu, Z., Li, J., Ke, Z., Li, Y., Song, J., Mo, L., & Zhu, C. (2026). Mechanistic insights into how Prevotella copri exacerbates tissue iron retention and chronic inflammation in β-thalassemia mice via activation of the JAK/STAT signaling pathway. Annals of Hematology. https://doi.org/10.1007/s00277-026-07320-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07320-6

Keywords: Prevotella copri, β-thalassemia, iron overload, JAK/STAT signaling pathway, chronic inflammation, gut microbiome, hepcidin, interleukin-6, ferroportin, ineffective erythropoiesis, Annals of Hematology, Mechanistic

Paroxysmal cold hemoglobinuria occupies a distinctive niche in hematology because of the peculiar behavior of the antibody responsible for it. The disorder is mediated by so-called biphasic Donath-Landsteiner antibodies, which have the unusual property of attaching themselves to red blood cells only at cold temperatures, such as those found in the capillaries of the extremities, and then triggering the destruction of those cells once they return to the warmer core of the body. This two-temperature mechanism gives the antibodies their biphasic character and explains the classic clinical hallmark of the disease: the passage of dark, hemoglobin-laden urine, often after exposure to cold. The antibody typically targets the P antigen, a carbohydrate structure found on the surface of red blood cells, and once bound it recruits complement, a cascade of blood proteins that punches lethal holes in the cell membrane, causing rapid and sometimes massive destruction of circulating red cells.

In children, PCH most often presents as a transient, self-limited illness that follows a viral infection and resolves on its own or with supportive care. In adults, the disease is considerably rarer, and when it does appear it raises two distinct possibilities: a post-infectious trigger, similar to the pediatric pattern, or an underlying hematologic malignancy that has dysregulated the immune system. The distinction matters enormously for management, because the adult form can be severe, relapsing, and tied to a serious underlying condition. The new report adds an important data point to the small literature on adult PCH by documenting a severe, life-threatening episode in an older adult and by carefully dissecting the diagnostic workup that confirmed the disease.

The patient at the center of the report was a 69-year-old man who first developed shingles, the painful blistering rash caused by reactivation of latent varicella-zoster virus that has remained dormant in nerve ganglia since a childhood chickenpox infection. Shortly afterward, he was diagnosed with COVID-19, and then he developed evidence of severe hemolysis, the rapid breakdown of red blood cells. The clinical timeline placed the onset of hemolysis after both infections, raising the possibility that either one, or both acting together, could have served as the immunologic trigger that set his immune system against his own red cells. The authors are careful to note that although the timeline is compatible with varicella-zoster reactivation triggering the disease, the specific infectious trigger cannot be definitively established, and the recent COVID-19 diagnosis represents a potential alternative trigger or co-trigger.

The diagnostic workup followed the standard logic of hemolytic anemia evaluation but arrived at an answer that required specialized testing. Initial hemolysis testing demonstrated a direct antiglobulin test, also known as a Coombs test, that was positive for complement component 3 but negative for immunoglobulin G. This pattern is a crucial clue: many autoimmune hemolytic anemias, particularly the warm-antibody type, show immunoglobulin G coating the red cells, whereas the complement-only pattern points toward a cold-reactive antibody such as the Donath-Landsteiner antibody. Confirmation came from Donath-Landsteiner testing, the definitive assay for the disease, which exploits the biphasic nature of the antibody by incubating the patient’s serum with red cells at cold temperature and then warming the mixture to demonstrate complement-mediated lysis.

Two additional findings on the patient’s blood smear aided the diagnosis and illustrate the value of careful microscopic examination. The smear showed erythrophagocytosis, the phenomenon in which white blood cells engulf red blood cells or their debris, and rosetting, in which red blood cells cluster around neutrophils in a flower-like arrangement. Both findings are commonly seen in PCH and reflect the intense inflammatory and phagocytic activity that complement-coated red cells provoke. In a disorder as rare as PCH, such morphological clues can be decisive, because clinicians may not initially suspect the diagnosis and the confirmatory Donath-Landsteiner test is not available in every laboratory.

The severity of the patient’s illness underscores that adult PCH is not a benign curiosity. His hospital course lasted 38 days and was described as complicated, requiring mechanical ventilation to support his breathing, renal replacement therapy in the form of dialysis to substitute for failing kidneys, and extensive transfusions to replace the red cells his immune system was destroying. Each of these interventions reflects a downstream consequence of massive hemolysis: the release of free hemoglobin into the circulation can injure the kidneys, severe anemia can starve tissues of oxygen, and the systemic inflammatory response can precipitate multi-organ failure. The report thus serves as a reminder that a condition often taught as a mild pediatric post-viral illness can, in adults, become a critical care emergency.

The immunologic story behind the case is also of interest to researchers studying how infections trigger autoimmunity. Varicella-zoster virus is a herpesvirus that establishes lifelong latency in sensory ganglia and can reactivate when immune surveillance wanes, as commonly happens with aging or immunosuppression. Molecular mimicry, in which antibodies generated against viral proteins cross-react with similar structures on host tissues, is one proposed mechanism linking viral infections to autoimmune blood disorders, and the P antigen on red cells has been discussed in this context. The concurrent COVID-19 diagnosis adds a further layer of complexity, since SARS-CoV-2 infection has itself been associated with a range of autoimmune hematologic complications, including autoimmune hemolytic anemia. Disentangling which infection, if either, drove the patient’s antibody production is not possible from a single case, and the authors explicitly decline to assign a definitive cause.

From a clinical practice standpoint, the case carries several lessons. First, PCH belongs on the differential diagnosis for any patient with acute hemolytic anemia and a complement-only positive direct antiglobulin test, particularly when there is a recent history of infection, and recognizing the characteristic smear findings of erythrophagocytosis and red cell rosetting can accelerate the diagnosis. Second, in adults with PCH, clinicians must search both for infectious triggers and for underlying hematologic malignancy, since the management and prognosis differ substantially between these scenarios. Third, the biphasic Donath-Landsteiner test remains the cornerstone of confirmation, and clinicians should advocate for it when the initial serologic pattern is suggestive, because misclassification as warm autoimmune hemolytic anemia could lead to ineffective treatment strategies such as corticosteroids or rituximab, which are mainstays for warm-antibody disease but have a less established role in PCH, where avoidance of cold exposure and supportive transfusion are central.

The report, published as an open-access case report and citable under DOI 10.1007/s00277-026-07310-8, was reviewed by the Thomas Jefferson University Privacy Office in accordance with institutional policy, and informed consent for publication was obtained from the patient. The authors declare no competing interests and received no funding for the manuscript. For the hematology community, the case expands the recognized spectrum of varicella-zoster-associated PCH from primary infection to viral reactivation, a distinction that matters for the growing population of older adults in whom shingles is common. For the broader medical readership, it is a vivid illustration of how a dormant virus and an unrelated pandemic-era infection can converge on a single patient’s immune system with dramatic consequences, and of how classical serologic techniques developed more than a century ago, when Donath and Landsteiner first described the antibody that bears their names, remain indispensable tools in modern diagnostic medicine.

Subject of Research: Paroxysmal cold hemoglobinuria following varicella-zoster virus reactivation and COVID-19

Article Title: An unusual trigger for a rare hemolytic anemia: paroxysmal cold hemoglobinuria after shingles and COVID-19

Article References: Mermelstein, A. G., Reilly, S. P., & Rhoades, R. (2026). An unusual trigger for a rare hemolytic anemia: paroxysmal cold hemoglobinuria after shingles and COVID-19. Annals of Hematology. https://doi.org/10.1007/s00277-026-07310-8

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07310-8

Keywords: paroxysmal cold hemoglobinuria, Donath-Landsteiner antibody, varicella-zoster virus, shingles, COVID-19, autoimmune hemolytic anemia, complement-mediated hemolysis, erythrophagocytosis, direct antiglobulin test, hematology, case report, Annals of Hematology

Primary thyroid lymphoma is a genuine medical rarity. The thyroid gland is packed with lymphatic tissue, particularly in people with chronic autoimmune inflammation such as Hashimoto’s thyroiditis, and on rare occasions a lymphoma can originate there directly rather than spreading from elsewhere in the body. Diffuse large B-cell lymphoma, or DLBCL, is the most common aggressive subtype of non-Hodgkin lymphoma overall, but when it presents as the first and only site of disease in the thyroid, it belongs to a small subset of so-called primary extranodal lymphomas. Because so few patients exist, no large randomized trials have ever defined a single standard of care. Treatment decisions are instead stitched together from small case series, registry data, and extrapolation from how DLBCL is managed at other anatomical sites. That evidence gap is precisely what the Hamburg team set out to address by pairing their patient’s story with a structured sweep of the published literature.

The clinical picture in 2017 was textbook for the disease in its most dangerous form. The patient’s enlarged thyroid was compressing her airway, explaining the dyspnoea and cough, while involvement of the recurrent laryngeal nerve that runs alongside the gland accounted for her hoarseness. Staging investigations placed her at Ann Arbor stage IE, meaning the lymphoma was confined to a single extranodal organ, and her International Prognostic Index score of 2 indicated intermediate risk. Histopathological analysis classified the tumor as the non-germinal-center B-cell-like, or non-GCB, subtype, a molecular categorization based on the cell of origin that carries prognostic weight in DLBCL generally. Establishing that classification reliably, the authors emphasize in their review, depends on obtaining an adequate tissue sample — ideally a core needle biopsy or a surgical biopsy — because fine-needle aspirates often cannot provide enough architectural and immunophenotypic detail to distinguish DLBCL from other thyroid malignancies or from inflammatory conditions.

First-line therapy followed the established chemoimmunotherapy playbook. The patient received R-CHOP, the workhorse regimen combining the anti-CD20 monoclonal antibody rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, together with prophylactic treatment directed at the central nervous system. Rituximab’s arrival two decades ago transformed outcomes in DLBCL by targeting the CD20 surface protein found on malignant B cells, and the literature review confirms that rituximab-containing chemoimmunotherapy remains the backbone of first-line treatment for primary thyroid DLBCL as well, occasionally supplemented with radiotherapy to the thyroid bed. Surgery, by contrast, played essentially no therapeutic role: across the reviewed literature, operations were largely confined to obtaining diagnostic tissue rather than attempting resection, a notable departure from how many solid thyroid cancers are managed with near-total thyroidectomy.

The initial response was complete remission, and for six years the patient remained disease-free. Then came the twist that makes this case report valuable to practicing hematologists. Rather than recurring locally in the same gland or spreading to distant lymph nodes, the lymphoma re-emerged as an isolated relapse in the contralateral thyroid lobe — the opposite side of the gland from the original tumor. Isolated late relapses of primary thyroid DLBCL are vanishingly rare; the review notes that relapsed or refractory disease in general, and central nervous system involvement in particular, are uncommon events in this patient population. The contralateral pattern raises intriguing questions about clonal biology: whether the relapse represented re-seeding from an occult residual clone within the gland or a truly independent second primary lymphoma arising in the same chronically inflamed tissue environment.

Treating a relapse six years after the original diagnosis posed a practical dilemma. Because the patient had already received anthracycline-based chemotherapy and rituximab, the team chose an off-label regimen abbreviated Pola-R-miniCHP. The key ingredient is polatuzumab vedotin, an antibody-drug conjugate that ferries a potent cytotoxic payload, monomethyl auristatin E, directly to CD79b, a component of the B-cell receptor complex expressed on malignant cells. Polatuzumab-based combinations have reshaped the landscape of relapsed and refractory DLBCL since demonstrating survival benefits in randomized testing, and the miniaturized chemotherapy backbone in this regimen was designed to reduce cumulative toxicity in an elderly patient. The gamble worked: the contralateral relapse again melted into complete remission, giving the patient two separate cures from the same rare disease across nearly a decade.

The literature review that accompanies the case report assembles the fragmented evidence base into a coherent picture. Reported five-year overall survival rates for primary thyroid DLBCL span a wide range, from 57 percent to 88 percent, reflecting heterogeneity in patient age, stage, histological subtype, and treatment era across the small published series. The better end of that spectrum approaches outcomes for early-stage DLBCL at more conventional nodal sites, underscoring that when the disease is caught while confined to the thyroid and treated promptly with modern immunochemotherapy, long-term survival is a realistic expectation. The authors also highlight that central nervous system relapse, a feared complication of aggressive DLBCL, appears infrequently in this population, which has implications for how aggressively clinicians need to pursue CNS-directed prophylaxis at diagnosis.

What the review cannot yet deliver is a definitive, evidence-based treatment guideline, and the authors are candid about why. The rarity of primary thyroid DLBCL means that every published series is small, retrospective, and vulnerable to selection bias. Randomized trials enrolling patients with this specific presentation are practically impossible to mount. Their proposed way forward is registry-based research, particularly studies that group primary extranodal DLBCLs of various origins together to achieve analyzable patient numbers while still capturing the distinctive features of thyroid disease. Such registries could clarify outstanding controversies, including the optimal role of radiotherapy consolidation, the necessity and duration of CNS prophylaxis, the value of molecular risk stratification, and how best to manage the rare relapses like the one documented in this report.

For the broader oncology community, the case carries several practical lessons. First, a rapidly enlarging thyroid mass with compressive or neurological symptoms in an older patient, especially one with background autoimmune thyroid disease, should prompt consideration of lymphoma alongside the more common carcinomas — because the diagnostic and therapeutic pathways diverge sharply, and inappropriate upfront surgery can delay the correct treatment. Second, adequate tissue via core needle or surgical biopsy is not a formality but the linchpin of accurate subtyping. Third, relapsed primary thyroid DLBCL, while exceptionally uncommon, may be amenable to the same novel agents that have improved salvage therapy for DLBCL elsewhere, as the successful off-label use of a polatuzumab-based regimen here demonstrates. The report thus functions as both a caution and an encouragement: vigilance at first presentation and flexibility at relapse can yield complete remissions even in a disease so rare that no guideline exists to follow.

The Hamburg authors, writing from one of Germany’s major university cancer centers, published their work open access so that clinicians encountering their own rare cases can consult the full analysis. As targeted immunotherapies continue to migrate from relapsed settings into frontline treatment across the lymphoma spectrum, the experience documented in this single patient may foreshadow how primary thyroid DLBCL is managed in the coming decade — with antibody-drug conjugates and other precision agents potentially joining or even replacing legacy regimens, and with international registries finally assembling enough patients to turn anecdote into evidence.

Subject of Research: Primary thyroid diffuse large B-cell lymphoma: diagnosis, treatment, and relapse management

Article Title: Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature

Article References: Kirkgöz, K., Weisel, K., Bokemeyer, C., & von Kroge, S. (2026). Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature. Annals of Hematology. https://doi.org/10.1007/s00277-026-07303-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07303-7

Keywords: primary thyroid lymphoma, diffuse large B-cell lymphoma, DLBCL, rituximab, R-CHOP, polatuzumab vedotin, thyroid cancer, non-Hodgkin lymphoma, relapse, chemoimmunotherapy, extranodal lymphoma, Annals of Hematology

The two endpoints at the heart of the analysis, spleen volume reduction (SVR) and transfusion independence (TI), have each been linked individually to improved survival in myelofibrosis before. What remained unclear, and what this study set out to resolve, is how the two responses behave when they occur together in the same patient. Spleen volume is typically measured by MRI or CT, with a reduction of at least 35 percent from baseline serving as the traditional regulatory benchmark for a clinically meaningful response. Transfusion independence, meanwhile, is defined as freedom from red blood cell transfusions over a specified period, reflecting restored or at least adequate natural blood cell production. Because myelofibrosis ravages the bone marrow, many patients require transfusions every few weeks, so breaking that dependency is one of the most tangible quality-of-life and survival milestones in the disease.

To interrogate the joint contribution of these endpoints, the researchers analyzed data from patients with primary myelofibrosis or myelofibrosis that had developed from polycythemia vera or essential thrombocythemia, all treated with momelotinib. The SIMPLIFY-1 trial enrolled patients who had never received a JAK inhibitor, while MOMENTUM enrolled patients whose disease had already been treated with another drug in that class, most commonly ruxolitinib. This distinction matters clinically, because JAK inhibitor–experienced patients represent a harder-to-treat population with fewer remaining options. In both trials, the researchers defined a dual response as the combination of transfusion independence with spleen volume reductions meeting one of four thresholds: at least 35, 25, 15, or 10 percent from baseline, all assessed at week 24 of treatment.

The results were strikingly consistent. Across every spleen volume reduction threshold examined, patients who achieved both transfusion independence and SVR at week 24 showed numerically longer overall survival than those who did not. In SIMPLIFY-1, the hazard ratios for death among dual responders ranged from 0.26 for the lowest threshold combination of at least 10 percent spleen reduction plus transfusion independence, with a 95 percent confidence interval of 0.16 to 0.43, up to 0.64 for the highest threshold of at least 35 percent plus transfusion independence, with a confidence interval of 0.38 to 1.10. A hazard ratio of 0.26 means dual responders at the lowest threshold faced roughly a quarter of the mortality risk of nonresponders during the observation period—a profound difference in a disease where median survival from diagnosis can be measured in just a few years.

The magnitude of the survival separation is perhaps best appreciated through the median overall survival figures. In SIMPLIFY-1, dual responders meeting the SVR10 plus TI criteria had a median overall survival of 120.8 months, compared with just 41.5 months for nonresponders—nearly a decade of additional survival. In MOMENTUM, the pattern held even in the more refractory, JAK inhibitor–pretreated population: dual responders showed hazard ratios of 0.33 for SVR10 plus TI (95 percent CI 0.17 to 0.65) and 0.32 for SVR35 plus TI (95 percent CI 0.11 to 0.88). Remarkably, median overall survival was not reached among dual responders in MOMENTUM for either threshold combination, while nonresponders had median survivals of 28.7 months for the SVR10 plus TI comparison and 32.0 months for the SVR35 plus TI comparison. For a population that has already failed a prior JAK inhibitor, survival curves that never reach a median during follow-up represent an exceptional outcome.

One of the most clinically important patterns in the data is that the separation of survival curves was most pronounced at the lowest spleen volume reduction thresholds of at least 10 and at least 15 percent. In other words, when a patient achieves or maintains transfusion independence on momelotinib, even a relatively modest shrinkage of the spleen appears sufficient to confer a survival advantage. This challenges the conventional wisdom that only the full 35 percent reduction—the standard endpoint used in drug approval trials—signals a meaningful survival benefit. The biological interpretation is that transfusion independence may serve as a proxy for the drug’s broader effect on the anemic, inflammatory milieu of myelofibrosis, so that once the transfusion need is controlled, smaller reductions in spleen size capture enough of the disease-modifying effect to matter for survival.

Momelotinib occupies a distinctive niche among JAK inhibitors precisely because of this anemia profile. Unlike other agents in its class, which can worsen anemia and thrombocytopenia—two of the most debilitating features of myelofibrosis—momelotinib additionally inhibits activin A receptor type 1, a signaling node that drives the iron-regulatory hormone hepcidin and contributes to the anemia of inflammation. That dual mechanism is thought to explain why momelotinib can improve or maintain hemoglobin levels while shrinking the spleen, making it particularly suited to the transfusion-dependent patient population that these analyses focus on. The new findings suggest that this anemia benefit is not merely a comfort measure; it may be a central component of the drug’s survival impact when paired with even modest spleen responses.

As with all post hoc analyses, important caveats apply. These were not pre-specified primary endpoints but retrospective subgroup comparisons within randomized trials, and patients who respond well to treatment early on may differ in other ways from those who do not, a phenomenon known as immortal time and confounding by indication. The authors note that the association between dual response and survival was consistent across both treatment-naive and JAK inhibitor–experienced populations, which strengthens the biological plausibility of the finding, but the analyses cannot definitively prove that the dual response itself causes the survival advantage. The work was sponsored by GSK, the manufacturer of momelotinib, and several authors are company employees, with the remaining academic investigators disclosing extensive consulting and advisory relationships with GSK and other pharmaceutical companies active in the myelofibrosis field.

Nevertheless, the practical implications for clinicians are considerable. Spleen volume and transfusion status are routinely assessed in myelofibrosis care, and the week 24 timepoint evaluated here falls early enough in the treatment course to inform real decisions about whether to continue, switch, or intensify therapy. If confirmed in prospective studies, the finding that a 10 to 15 percent spleen reduction combined with transfusion independence marks a survival advantage could reshape how physicians interpret early imaging results, sparing patients whose modest but genuine responses might otherwise be judged inadequate under the traditional 35 percent benchmark. It could also inform the design of future clinical trials, where dual response at lower SVR thresholds might serve as a more sensitive surrogate endpoint for survival.

For patients, the message is one of cautious hope. Myelofibrosis remains a formidable disease, and allogeneic stem cell transplantation—the only curative option—is available to only a minority due to age and comorbidities. But the growing arsenal of targeted therapies, and the accumulating evidence that meaningful responses can be recognized earlier and at lower thresholds than previously assumed, is steadily changing the prognosis. These analyses, presented in part at the 2025 annual meeting of the American Society of Hematology, add a crucial piece to that picture: in the era of momelotinib, the combination of a smaller spleen and a full blood count sustained without donor blood may be one of the strongest early signals that a patient is living longer with their disease.

Subject of Research: Association of dual transfusion independence and spleen volume reduction with overall survival in myelofibrosis patients treated with momelotinib

Article Title: Dual transfusion independence and spleen volume reduction are associated with overall survival in patients with myelofibrosis treated with momelotinib: post hoc analyses of SIMPLIFY-1 and MOMENTUM

Article References: Palandri, F., Schaap, N. P. M., Rey, J., von Bubnoff, N., Reiter, A., Hernández-Boluda, J. C., Devos, T., Psaila, B., McLornan, D. P., Ellis, C., Zhang, S., Kim, S., & Oh, S. T. (2026). Dual transfusion independence and spleen volume reduction are associated with overall survival in patients with myelofibrosis treated with momelotinib: post hoc analyses of SIMPLIFY-1 and MOMENTUM. Annals of Hematology. https://doi.org/10.1007/s00277-026-07299-0

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07299-0

Keywords: myelofibrosis, momelotinib, transfusion independence, spleen volume reduction, overall survival, JAK inhibitor, SIMPLIFY-1, MOMENTUM, hematology, clinical trials, anemia, Annals of Hematology

A team of hematologists and oncologists affiliated with the Bavarian Cancer Research Center (BZKF) conducted a multi-center retrospective analysis of lymphoma patients who contracted COVID-19 at five tertiary care centers in Germany between March 2020 and March 2022. The centers involved span some of the country’s largest university hospitals, including LMU University Hospital Munich, TUM University Hospital, University Hospital Erlangen, University Hospital Regensburg, and University Hospital Augsburg. By pooling anonymized routine clinical data across these institutions, the investigators assembled a cohort large enough and sufficiently granular to compare baseline characteristics, treatment decisions, and clinical outcomes across distinct pandemic waves. The study, led by Stefanie Forkl and Johannes C. Hellmuth of LMU Munich, was published as a brief report in the journal Annals of Hematology and received ethics approval from the medical faculty of LMU Munich.

The central finding is striking in its clarity. In the most recent pandemic wave covered by the analysis — defined as infections occurring after December 27, 2021, when the Omicron variant dominated transmission in Germany — severe COVID-19 courses were recorded in only 4 of 40 lymphoma patients. In the earlier waves, by contrast, 26 of 73 patients experienced severe disease. This difference was statistically significant, with a p-value of 0.03. Mortality followed the same pattern: two of the 40 patients in the late wave died, compared with 14 of the 73 patients infected earlier in the pandemic, a difference that also reached statistical significance at p = 0.039. In proportional terms, the case fatality rate fell from roughly 19 percent in the earlier period to 5 percent in the most recent wave, while the rate of severe disease dropped from about 36 percent to 10 percent.

The authors attribute this improvement not to any single intervention but to the convergence of several protective factors that changed the clinical landscape between 2020 and early 2022. Vaccination coverage among lymphoma patients rose dramatically over the study period. In the final pandemic wave, 88 percent of the infected lymphoma patients had received at least partial vaccination before their SARS-CoV-2 infection, a level of coverage that was essentially absent during the first waves of 2020. This matters even in a population known to mount attenuated antibody responses, because cellular immunity, hybrid immunity from prior infection, and residual humoral responses all contribute to protection against severe disease even when neutralizing antibody titers are suboptimal.

Therapeutic options expanded in parallel. Once infected, 57 percent of the lymphoma patients in the most recent wave were treated with neutralizing monoclonal antibodies, and 35 percent received antiviral agents. Neither class of drug was available in the early months of the pandemic. Monoclonal antibodies such as those directed against the SARS-CoV-2 spike protein offered passive immunization that could compensate for the blunted endogenous antibody responses typical of patients treated with CD20-depleting agents like rituximab, which eliminate the B cells responsible for antibody production. Antiviral drugs, meanwhile, provided a mechanism of protection independent of the patients’ own immune competence, directly inhibiting viral replication during the critical early phase of infection.

The technical significance of this study lies in its wave-by-wave comparison within a single, well-characterized patient population. Many earlier analyses of COVID-19 in hematologic malignancies pooled cases across the entire pandemic or focused on a single center, making it difficult to separate the effects of evolving viral variants, changing patient management, and the natural heterogeneity of lymphoma subtypes. By stratifying outcomes by calendar period and documenting vaccination status and pharmacologic treatment for each case, the BZKF registry provides a longitudinal view of how the intersection of a vulnerable immune state and a shifting pandemic environment determined clinical risk. The consistency of the improvement across both severity and mortality endpoints strengthens the conclusion that the change is real rather than a statistical artifact.

At the same time, the investigators are careful about causal attribution. Because vaccination, monoclonal antibody therapy, antiviral treatment, and the transition to the less virulent Omicron variant all occurred roughly simultaneously, the retrospective design cannot cleanly disentangle the relative contribution of each factor to the observed improvement. A patient infected in early 2022 differed from one infected in 2020 in nearly every relevant dimension: the circulating variant, the immune history, the drugs available, and the accumulated clinical experience of the treating teams. The authors explicitly acknowledge this limitation, noting that while they cannot clearly distinguish the individual effects of each intervention, the aggregate data demonstrate that severity and mortality of COVID-19 in this vulnerable population have recently declined.

For clinicians managing lymphoma patients, the practical implications are nonetheless substantial. The authors conclude that their data largely support a return to pre-pandemic treatment recommendations and protocols for this patient group. During the acute phases of the pandemic, many cancer centers deferred or modified lymphoma therapy, delayed rituximab-containing regimens, and imposed restrictive isolation measures out of concern that immunosuppression would amplify COVID-19 risk. The new findings suggest that such extraordinary caution is no longer proportionate to the residual risk, provided that patients are vaccinated and that breakthrough infections are treated promptly with the antiviral and antibody-based agents now available. This does not mean vigilance can be abandoned entirely — a 5 percent mortality rate among infected patients remains far higher than in the general population — but it marks a meaningful recalibration of the risk-benefit calculus that governed oncology practice during the pandemic’s peak.

The study also underscores the enduring value of disease-specific registries during public health emergencies. The COVID-19-lymphoma registry of the BZKF was built on the infrastructure of an established regional cancer research consortium, allowing rapid, coordinated data collection across five centers without the delays that typically accompany prospective trials in rare populations. Lymphoma patients are heterogeneous — the category encompasses indolent and aggressive B-cell malignancies, T-cell lymphomas, Hodgkin lymphoma, and patients at vastly different points in their treatment trajectories — and only registry-scale efforts can capture enough cases to draw meaningful conclusions about outcomes in subgroups defined by both malignancy and pandemic timing. Similar registry models have proven their worth for other immunocompromised populations and represent a template for future infectious disease threats.

As the pandemic recedes from daily attention, studies like this one serve as a quantitative record of how clinical outcomes evolved in the populations hit hardest. For lymphoma patients in Bavaria and, by extension, in comparable health systems across Europe and North America, the trajectory from 2020 to 2022 was one of genuine improvement: vaccination rates approaching 90 percent, widespread access to passive and antiviral therapies, and a decline in severe disease and death to a fraction of earlier levels. The residual risks are real and warrant continued attention to vaccination schedules, pre-exposure prophylaxis where appropriate, and early treatment of breakthrough infections. But the central message of the BZKF registry is ultimately an encouraging one — that the convergence of immunization, targeted therapeutics, and clinical experience substantially tamed what was once one of the most feared complications facing patients with cancer of the immune system.

Subject of Research: COVID-19 outcomes in lymphoma patients across pandemic waves

Article Title: Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020–2022

Article References: Forkl, S., Freudenberger, F., Jacobs, B., Einhell, S., Hirschbuehl, K., Claus, R., Hellwig, D., Mougiakakos, D., Dreyling, M., Illert, L., Heidegger, S., Weigert, O., & Hellmuth, J. C. (2026). Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020–2022. Annals of Hematology, 105(9), Article 401. https://doi.org/10.1007/s00277-026-07094-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07094-x

Keywords: COVID-19, lymphoma, BZKF registry, vaccination, monoclonal antibodies, antiviral therapy, rituximab, CD20-depleting therapy, immunocompromised patients, Omicron variant, Annals of Hematology, hematologic malignancies

The numbers are striking. Among 54 patients followed for a median of 10 months, 98.1 percent achieved at least one lactate dehydrogenase value at or below 1.5 times the upper limit of normal, the standard biochemical signature that red-cell destruction has been brought to heel. Even more consequential for daily life, 85.2 percent reached hemoglobin concentrations of 120 grams per liter or higher, a threshold that generally marks the boundary between anemia and normal oxygen-carrying capacity. And in a finding that will resonate with every patient who has scheduled life around transfusion appointments, all 20 patients who were transfusion-dependent at the start of treatment became transfusion-independent.

To understand why those results matter, it helps to look at the molecular machinery involved. In PNH, a somatic mutation in the PIGA gene eliminates the glycosylphosphatidylinositol anchors that hold protective proteins such as CD55 and CD59 to the surface of blood cells. Without CD59, the membrane attack complex, a barrel-shaped assembly of complement proteins that punches lethal holes in cell membranes, forms freely on red cells, and chronic intravascular hemolysis follows. Free hemoglobin spills into the plasma, scavenges nitric oxide, and drives the smooth-muscle spasms, abdominal pain, erectile dysfunction, and pulmonary hypertension that make the disease so debilitating. The same uncontrolled complement activation consumes platelets’ protection and fuels the thromboses that historically made PNH one of the deadliest benign hematologic conditions.

The first generation of targeted therapy, the anti-C5 antibodies eculizumab and ravulizumab, transformed that prognosis by blocking the terminal step of the complement cascade. But C5 inhibition has a structural limitation: it stops the membrane attack complex while leaving the upstream alternative pathway running. Red cells coated with C3 fragments survive destruction in the bloodstream only to be cleared by macrophages in the spleen and liver, a process called extravascular hemolysis that keeps many patients anemic and transfusion-dependent. Roughly a quarter of patients on C5 inhibitors continue to require transfusions, and some experience breakthrough hemolysis when complement activation overwhelms the drug.

Iptacopan takes a different route. As a small-molecule inhibitor of factor B, it shuts down the alternative pathway at its point of amplification, upstream of both C3 opsonization and terminal complex formation. In theory, that should prevent intravascular hemolysis and the C3-coated red cells that fuel extravascular hemolysis, addressing the disease at a more fundamental level. The pivotal phase three APPOINT-PNH trial, which enrolled complement inhibitor-naive patients internationally, demonstrated exactly that, with most participants achieving hemoglobin normalization without transfusions and earning the drug regulatory approvals in the United States, Europe, and elsewhere as the first oral monotherapy for PNH.

What the new Chinese study adds is evidence from a real-world population outside the tightly controlled boundaries of a registration trial. The 54 patients, 17 of them women, had a median age of 38 years and ranged from 21 to 82, drawn from a network of hospitals spanning Beijing, Wuhan, Chengdu, Zhengzhou, Taiyuan, Kunming, and other cities. The investigators tracked clinical and laboratory indicators at one, three, and six months after starting iptacopan and through subsequent follow-up. Notably, the benefits held across disease subtypes: patients with classic hemolytic PNH and those with an aplastic anemia-PNH overlap syndrome, in which bone marrow failure compounds the hemolysis, showed no significant differences in their hemolytic parameters on treatment.

Safety, always the second half of the efficacy equation, was equally reassuring. The most common adverse events were headache and upper respiratory tract infection, each affecting 13 percent of patients. Breakthrough hemolysis, the feared scenario in which hemolysis resumes despite therapy, occurred in only 7.4 percent of the cohort. The study recorded no new thrombotic or microvascular events, no extravascular hemolysis, and, critically, no breakthrough infections with Neisseria meningitidis or Streptococcus pneumoniae, the encapsulated bacteria against which complement pathway blockade raises a well-known shield. Meningococcal infection is the reason all complement inhibitor users require vaccination and vigilance, and its complete absence in this cohort, while reassuring, underscores that the follow-up window remains relatively short.

The retrospective design carries inherent caveats that the authors and independent observers alike will emphasize. Without randomization or a control group, the study cannot exclude the influence of selection bias, and the median follow-up of 10 months, with a range of 6 to 18, leaves long-term durability, cumulative toxicity, and pregnancy outcomes open questions. Laboratory monitoring schedules varied across the many participating centers, and the analysis of patients who discontinued treatment or required dose adjustments will be scrutinized as the full paper circulates. Still, the consistency of the findings with the phase three data, in a health system and genetic background not represented in the original trials, strengthens the case that the drug’s benefits generalize.

For Chinese patients, the practical implications are immediate. Before factor B inhibitors, the standard of care in much of China, as in many middle-income countries, was limited by the cost and intravenous infrastructure demands of C5 monoclonal antibodies, leaving many patients managed with transfusions, iron supplementation, and anticoagulation alone. An oral agent that can be prescribed across a network of provincial hospitals, and that returned every transfusion-dependent patient in this cohort to transfusion independence, represents a meaningful shift in what standard care can look like outside major academic centers.

The broader scientific story is equally compelling. PNH was the first disease in which a clonal hematopoiesis was shown to be rescued not by eliminating the mutant clone but by pharmacologically disarming the selective pressure it exploited, a conceptual template now being applied across complement-mediated disorders, from IgA nephropathy to C3 glomerulopathy. Iptacopan’s real-world performance in China, with sustained hemolytic control, significant hemoglobin improvement, and a favorable safety profile, confirms that the alternative pathway is a druggable Achilles’ heel of this disease. As longer follow-up accumulates and prospective studies in additional populations mature, the question is shifting from whether oral factor B inhibition works to how best to sequence, monitor, and eventually tailor complement blockade to each patient’s biology, a question that the next decade of PNH research is now well positioned to answer.

Subject of Research: Real-world efficacy and safety of the oral complement factor B inhibitor iptacopan in Chinese patients with paroxysmal nocturnal hemoglobinuria

Article Title: Iptacopan treatment for chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): a multicenter retrospective study

Article References: Wang, L., Zhang, M., Chang, H., Zhou, H., Ma, S., Ma, Y., Miao, D., Zhou, Z., Jia, J., Zhang, R., Zhang, G., Liu, J., Zhu, Q., Yu, B., Wang, H., Hou, R., Ge, W., Wang, L., Lang, J., … Han, B. (2026). Iptacopan treatment for chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): a multicenter retrospective study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07230-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07230-7

Keywords: paroxysmal nocturnal hemoglobinuria, iptacopan, complement inhibitor, factor B, hemolysis, hemoglobin, transfusion independence, alternative pathway, breakthrough hemolysis, retrospective study, Annals of Hematology, China

The study, led by Gianni Binotto of the University of Padova and Carmen Fava of the University of Turin, together with colleagues from major Italian haematology centres in Milan, Turin, Bari, Pavia and Bologna, focused on six adult patients with Philadelphia chromosome–positive chronic myeloid leukaemia in chronic phase. This form of leukaemia is defined by a characteristic genetic swap between chromosomes 9 and 22, which creates the BCR-ABL1 fusion gene encoding a constitutively active tyrosine kinase. It is this rogue enzyme that tyrosine kinase inhibitors are designed to block, and the Philadelphia chromosome serves as the molecular fingerprint of the disease. All six patients in the series had already been exposed to at least two prior tyrosine kinase inhibitors and had either become resistant to them or suffered intolerable side effects, placing them among the most challenging cases that clinicians encounter in routine practice.

What set these patients apart was not only their treatment history but their overall health profile. The cohort carried a substantial burden of comorbidities, predominantly cardiovascular in nature. Hypertension, peripheral arterial disease, ischaemic heart disease and metabolic disorders featured prominently among their conditions. This detail matters because several first- and second-generation tyrosine kinase inhibitors, notably nilotinib and ponatinib, have been associated with arterial occlusive events, including heart attacks, strokes and peripheral vascular complications. For patients whose blood cancer is under control but whose arteries are compromised, the choice of therapy becomes a delicate balancing act between suppressing the leukaemia and protecting the cardiovascular system. Asciminib, with its distinctive mechanism of action, has been proposed as a particularly attractive option for exactly this population.

The reason lies in the drug’s unusual binding mode. Whereas earlier tyrosine kinase inhibitors target the ATP-binding site of the ABL1 kinase, asciminib selectively targets the myristoyl pocket, a regulatory region of the protein that is otherwise not exploited by any other approved drug in the class. This allosteric mechanism gives asciminib high specificity for its target and is thought to underpin its potentially improved safety profile. Because the myristoyl pocket is a distinct structural feature of ABL1, the drug can remain active against certain mutations that confer resistance to ATP-site competitors. Among these is the notorious T315I mutation, often described as the most formidable resistance mutation in chronic myeloid leukaemia, which has historically limited treatment options dramatically. Asciminib’s efficacy has been demonstrated in both clinical trials and real-world settings, including heavily pretreated patients and those carrying the T315I mutation, making it a valuable addition to the therapeutic arsenal.

In the Italian case series, asciminib was administered for a median duration of 16.5 months, providing a meaningful window in which to observe both efficacy and tolerability. The results were strikingly consistent. All six patients achieved or maintained clinically meaningful molecular responses, including major molecular responses and deep molecular responses. These endpoints are measured by tracking the level of BCR-ABL1 transcript in the blood using sensitive polymerase chain reaction assays, and deeper responses correlate with better long-term outcomes and, in some cases, the possibility of treatment-free remission. For patients who had already cycled through multiple therapies without success, the ability of asciminib to induce or sustain such responses represents a significant clinical benefit.

Equally important was the drug’s tolerability. Treatment was well tolerated across the cohort, with no discontinuations due to adverse events. No arterial occlusive events were observed, and no significant cardiovascular worsening occurred during the observation period. This is a notable finding given the cardiovascular vulnerability of the patients involved. Even more remarkably, no haematologic toxicity was recorded, even in a patient with underlying bone marrow hypoplasia, a condition in which the bone marrow’s capacity to produce blood cells is already diminished. Myelosuppression is a common concern with many anticancer therapies, and the absence of this toxicity in a compromised patient suggests that asciminib’s high target specificity translates into a genuinely gentler profile at the level of normal blood-forming tissue.

The authors are careful to frame these observations appropriately. With only six patients, the series cannot deliver the statistical power of a randomised trial, and the findings are presented as a summary of the drug’s clinical data alongside real-world experience rather than as definitive evidence. Nevertheless, the study argues that real-world data of this kind play an essential role in supporting treatment decisions, because patients seen in everyday practice are often older, more comorbid and more heavily pretreated than those enrolled in pivotal clinical trials. Regulatory trials typically exclude individuals with uncontrolled hypertension, prior arterial events or reduced bone marrow reserve, precisely the characteristics that defined this Italian cohort. Demonstrating that asciminib can be used safely and effectively in such patients fills an important evidence gap that trial data alone cannot address.

The broader context of chronic myeloid leukaemia treatment makes these findings resonate. Since the introduction of imatinib at the turn of the millennium, survival in chronic myeloid leukaemia has risen to near-normal life expectancy for many patients, turning a fatal disease into a chronic condition managed with daily oral therapy. But this success has created its own challenges: patients now live for decades with their disease and their medication, so long-term tolerability, cardiovascular safety and quality of life have become central concerns. Second-generation inhibitors improved response rates but introduced new toxicity profiles, and resistance mutations continue to emerge. Drugs that combine deep molecular activity with a favourable cardiovascular and haematologic safety profile address the most pressing unmet needs in the field, particularly for the growing population of long-term survivors with age-related comorbidities.

Asciminib’s allosteric mechanism also represents a conceptual milestone in targeted cancer therapy. Rather than competing with ATP at the active site, the drug locks the kinase into its inactive conformation by engaging a pocket used naturally by the protein’s own regulatory lipid, myristate. This approach, sometimes described as a STAMP inhibitor, an acronym for specifically targeting the ABL myristoyl pocket, illustrates how structural biology can be exploited to design molecules with exquisite selectivity. The Italian case series adds a practical, bedside-level dimension to this molecular story, showing that the elegance of the mechanism is reflected in clinical outcomes for patients who have few alternatives left.

For clinicians managing chronic myeloid leukaemia, the message from this small study is one of cautious encouragement. In a real-world cohort of heavily pretreated patients with substantial comorbidity burden, asciminib demonstrated sustained efficacy and a favourable safety profile, with cardiovascular tolerability standing out as a particular strength. The authors conclude that these findings reinforce the potential role of asciminib for patients with resistance or intolerance to multiple tyrosine kinase inhibitors, as well as for those at high cardiovascular risk. As more real-world data accumulate across centres and countries, the picture of who benefits most from this allosteric inhibitor will continue to sharpen, helping physicians tailor therapy to the individual patient rather than to the average trial participant. For the six Italian patients documented here, and for the many others like them worldwide, that individualisation may make all the difference between merely surviving with leukaemia and truly living well with it.

Subject of Research: Real-world efficacy and safety of the allosteric BCR-ABL1 inhibitor asciminib in heavily pretreated chronic myeloid leukaemia patients

Article Title: Real-world Italian experience with asciminib in chronic myeloid leukaemia–chronic phase: case series and drug profile overview

Article References: Binotto, G., Cattaneo, D., Di Biase, F., Ditonno, P., Elena, C., Restuccia, R., & Fava, C. (2026). Real-world Italian experience with asciminib in chronic myeloid leukaemia–chronic phase: case series and drug profile overview. Annals of Hematology. https://doi.org/10.1007/s00277-026-07284-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07284-7

Keywords: asciminib, chronic myeloid leukaemia, tyrosine kinase inhibitors, BCR-ABL1, myristoyl pocket, cardiovascular safety, molecular response, T315I mutation, real-world evidence, haematology, drug resistance, Annals of Hematology

The gold standard for measuring iron in the heart muscle is cardiac magnetic resonance imaging using a parameter known as T2*. When tissue is loaded with iron, it disrupts the magnetic signals in a way that shortens the T2* relaxation time, so a low T2* value directly indicates heavy iron deposition. The technique is powerful and validated, but it comes with practical burdens. MRI scanners are expensive, require specially calibrated sequences, demand sedation or exceptional cooperation from young children, and are simply unavailable in many of the hospitals where thalassemia care is delivered. In much of South Asia, sub-Saharan Africa, and other high-burden regions, a child may receive transfusions for years without ever having a single cardiac MRI. That gap between need and access is precisely what a team of pediatricians, cardiologists, and community medicine specialists at Bharati Vidyapeeth Deemed University in Pune set out to address.

Their tool of choice was two-dimensional speckle-tracking echocardiography, or 2DSTE, an advanced form of ultrasound analysis that has been gaining ground in cardiology over the past two decades. Standard echocardiography measures how much the heart shortens and pumps, expressed as the ejection fraction, but this familiar number is notoriously insensitive. The heart can compensate for subtle injury by working harder, keeping the ejection fraction deceptively normal even as the muscle stiffens and weakens at the microscopic level. Speckle-tracking works differently. Software tracks the natural acoustic markers, or speckles, within the heart muscle frame by frame, measuring how far each tiny region of tissue moves and deforms throughout the cardiac cycle. The result is a measure called strain, typically reported as global longitudinal strain, which quantifies the percentage of shortening of the heart muscle along its long axis. Because strain detects deformation rather than just overall pumping, it can reveal dysfunction years before the ejection fraction drops.

In the study, the researchers enrolled 90 children with transfusion dependent thalassemia along with 47 healthy controls of comparable age. The patients had a mean age of 11 years, and just over two-thirds were male, while the controls averaged just over 10 years of age. Every participant underwent conventional transthoracic echocardiography as well as speckle-tracking analysis, with the strain values calculated from multiple standard imaging views: the two-chamber, three-chamber, and four-chamber planes, plus an averaged global value. For the patients, the investigators also compared these measurements against cardiac MRI T2* values, which were obtained in those old enough to undergo the scan without difficulty. The design is a classic diagnostic accuracy framework, asking a deceptively simple question: can the bedside ultrasound test find what the expensive reference standard finds?

The first, and in some ways most striking, finding was how silent the damage is. When the researchers compared conventional echocardiographic parameters between the thalassemia children and the healthy controls, almost nothing differed. Left ventricular ejection fraction, the number most cardiologists quote first, was essentially indistinguishable between the two groups. Only the Doppler-derived filling measures, the E/A ratio and the E/e’ index, which reflect how the heart relaxes and fills with blood, showed any difference. Even the global longitudinal strain values, while higher in the patient group in a direction suggesting altered deformation, did not reach statistical significance when patients were compared with controls as a whole. In other words, a routine echocardiogram would have reassured the families of nearly all of these children, even those quietly accumulating iron in their myocardium.

The picture changed when the children were sorted by their actual iron burden. Sixty-three of the 90 patients underwent cardiac MRI, and 23 of them had T2* values above 20 milliseconds, the threshold that defines the absence of significant cardiac loading. The remaining 40 children fell below that cutoff and were classified as having cardiac iron loading. When the researchers compared conventional echocardiography between these two subgroups, it again failed to separate them. But global longitudinal strain told a different story. The strain values were significantly higher in the iron-loaded group, with a p value below 0.001, indicating that the speckle-tracking measurement was detecting myocardial changes that the standard pump function measures completely missed. Iron-damaged heart muscle becomes stiffer and less compliant, and strain imaging appears to register that stiffening even while the chamber still empties normally.

To translate the finding into clinical practice, the team performed receiver operating characteristic analysis, the standard statistical method for determining how well a test discriminates between disease states and where to place the diagnostic threshold. The analysis identified an average global longitudinal strain cutoff of less than negative 20.01 as the optimal predictor of cardiac iron overload. At that threshold, the test caught 70 percent of children who truly had cardiac loading, the sensitivity figure, while correctly clearing 87 percent of those who did not, the specificity. Perhaps most clinically meaningful was the positive predictive value of 90.3 percent: when the strain test flagged a child as iron-loaded, that flag was correct more than nine times out of ten. The negative predictive value of 62.5 percent was more modest, meaning a reassuring strain result could not fully exclude iron loading, which is why the authors position the technique as a complement to MRI rather than a replacement.

Those performance characteristics matter enormously in the settings where the burden of thalassemia is heaviest. An echocardiography machine is a fraction of the cost of an MRI scanner, requires no sedation, produces results in minutes, and exists in district hospitals across the developing world. A screening strategy built around speckle-tracking could therefore triage which children most urgently need MRI confirmation and chelation intensification, reserving the scarce MRI resource for those the ultrasound flags as high risk. In a child whose strain values cross the threshold, the care team could escalate iron chelation therapy, the treatment that removes excess iron from the body, before irreversible cardiac injury takes hold. The authors conclude that 2DSTE may be a useful adjunct for early detection of cardiac iron overload and may complement cardiac T2* MRI in resource-limited settings, a formulation that reflects both the promise and the residual uncertainty of the approach.

The study does have limitations that temper enthusiasm. The MRI comparison was available only for children older than eight years, leaving the youngest patients, who are often the most vulnerable to cumulative iron exposure, outside the reference standard analysis. The sample of 63 scanned patients, while adequate for the statistical analysis performed, is modest by the standards of large multicenter diagnostic trials, and the cutoff values will need validation in independent cohorts before they can be adopted universally. Strain measurements are also known to vary somewhat between ultrasound vendors and image quality conditions, a technical hurdle the field has been working to standardize. The authors acknowledged assistance from a language model for grammar and syntax while reviewing and approving the final content, and the work was supported by an in-house institutional grant with no role for the funder in the study design or analysis.

Even with those caveats, the study adds to a growing body of evidence that deformation imaging can unmask subclinical myocardial disease across a range of conditions, from chemotherapy toxicity to amyloidosis to, now, iron overload. For the global thalassemia community, the implications are immediate and practical. Children in Pune, and potentially children in any clinic with an ultrasound machine and trained staff, could soon be screened for the complication most likely to shorten their lives using equipment they can access today rather than the scanner they may never reach. Early identification is the entire game in cardiac iron overload, because chelation works best when the heart has not yet been structurally remodeled. If larger studies confirm the Pune team’s numbers, a routine ultrasound measurement that takes minutes at the bedside could become the difference between a child who grows up with a healthy heart and one who discovers, too late, that the transfusions keeping them alive were silently stealing it.

Subject of Research: Early detection of cardiac iron overload in children with transfusion dependent thalassemia using speckle-tracking echocardiography compared with cardiac MRI T2*

Article Title: Early identification of cardiac iron overload in children with transfusion dependent thalassemia using two-dimensional speckle-tracking echocardiography and its comparison with cardiac MRI T2*: a diagnostic accuracy study

Article References: Hanumante, N., Bafna, V., Patil, V., Chowhan, V., Doke, P., Baheti, A., & Deshmukh, R. (2026). Early identification of cardiac iron overload in children with transfusion dependent thalassemia using two-dimensional speckle-tracking echocardiography and its comparison with cardiac MRI T2*: a diagnostic accuracy study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07286-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07286-5

Keywords: transfusion dependent thalassemia, cardiac iron overload, speckle-tracking echocardiography, global longitudinal strain, cardiac MRI T2*, diagnostic accuracy, pediatric cardiology, iron chelation, echocardiography, left ventricular ejection fraction, resource-limited settings, Annals of Hematology

The research, published in Annals of Hematology by a team led by Jiayuan Guo, Liuqing Huang, Zixuan Li, and senior authors Liping Dou, Zhenyang Gu, and Chunji Gao, examined 106 consecutive patients who underwent allogeneic hematopoietic stem cell transplantation at a single institution between January 2010 and January 2025. Of these, 71 had T-cell acute lymphoblastic leukemia and 35 had T-cell lymphoblastic lymphoma. Allogeneic transplantation, in which a patient receives blood-forming stem cells from a genetically matched donor, remains one of the most intensive therapies in medicine, replacing a patient’s entire immune and hematopoietic system with that of another person. It is typically reserved for patients with high-risk or relapsed disease, making the question of which diagnosis benefits most from the procedure clinically urgent.

The headline finding is one of equivalence. The researchers detected no statistically significant differences between the two groups in overall survival, disease-free survival, or graft-versus-host disease-free, relapse-free survival, a composite measure that captures the three main threats facing transplant recipients: death, relapse, and chronic immune complications. Nor did the cumulative incidence of relapse or the cumulative incidence of non-relapse mortality, which counts deaths from transplant-related causes such as infection and organ damage rather than from returning cancer, differ meaningfully between the leukemia and lymphoma cohorts. In multivariable analyses that adjusted for other clinical variables, the diagnosis itself was not associated with any of these outcomes.

That overall equivalence, however, conceals a more nuanced temporal story. Using time-dependent statistical models, the team found that the effect of diagnosis on survival changed over the course of follow-up. At six months after transplantation, patients with T-cell lymphoblastic lymphoma had worse overall survival than those with leukemia, with a time-specific hazard ratio of 2.41 and a 95 percent confidence interval of 1.10 to 5.28, a statistically significant difference. This early vulnerability likely reflects the particular hazards of the immediate post-transplant period, when conditioning regimens, infections, and acute immune reactions claim the greatest toll.

By 36 months, the picture had reversed. At that later time point, T-cell lymphoblastic lymphoma was associated with a lower risk of disease-free survival failure, with a hazard ratio of 0.16, and a dramatically lower risk of non-relapse mortality, with a subdistribution hazard ratio of just 0.06. In other words, lymphoma patients who survived the critical first months appeared to enjoy a safer long-term course than their leukemia counterparts. Consistent with this, the restricted mean survival time analysis, which quantifies average survival over a fixed window, showed that the 36-month restricted mean survival time for overall survival was 5.79 months shorter in the lymphoma group, a statistically significant gap, while disease-free and graft-versus-host disease-free, relapse-free survival showed no significant differences by this measure.

The researchers also observed that moderate to severe chronic graft-versus-host disease, a debilitating condition in which donor immune cells attack the recipient’s healthy tissues, was less frequent among patients with T-cell lymphoblastic lymphoma. This difference persisted in propensity score-matched cohorts, a technique that pairs patients from the two groups with similar baseline characteristics to reduce the confounding that plagues observational comparisons. Most other outcomes, however, remained indistinguishable between the matched groups, reinforcing the central conclusion that diagnosis alone does not determine transplant success.

The study’s robustness was tested in several ways. Complete case analyses focusing on white blood cell count and lactic dehydrogenase, two markers of disease burden that are often elevated in aggressive lymphoid malignancies, did not materially change the estimates. Nor did analyses restricted to patients in complete remission with evaluable measurable residual disease, the sensitive molecular test that detects tiny quantities of malignant cells below the threshold of microscopic examination. These sensitivity analyses suggest that the equivalence finding is not an artifact of missing data or of comparing patients at different disease stages.

The scientific backdrop to this work is a quiet revolution in how these two diseases are understood. Historically unified as a single entity, T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma have been increasingly distinguished by molecular diagnostics and cytogenetic testing, which have revealed inherent differences in their genetic signatures and chromosomal profiles. Yet comparative outcome data following allogeneic transplantation had remained scarce, leaving transplant physicians without a firm evidence base for counseling patients from the two diagnostic groups. This study, spanning fifteen years of consecutive transplants, helps fill that gap.

The clinical implications are straightforward. For patients and physicians weighing the risks and benefits of allogeneic transplantation, the diagnosis of leukemia versus lymphoma should not, on its own, drive the decision. Instead, the findings suggest that other factors, such as disease status at transplant, measurable residual disease, donor type, and patient comorbidities, remain the more meaningful predictors of outcome. The early survival disadvantage seen in lymphoma patients may warrant heightened vigilance during the first six months after transplant, while the lower late non-relapse mortality offers some reassurance for long-term survivors.

The authors are careful to frame their conclusions with appropriate caution. As a single-center retrospective study of 106 patients, the analysis lacks the statistical power of a large multicenter trial, and the time-dependent effects observed, while statistically significant, rest on modest numbers of events at each time point. The team explicitly calls for confirmation in larger multicenter studies. Still, the work represents one of the most detailed head-to-head comparisons of these two diagnoses in the transplant setting to date, and it delivers a message that is both scientifically interesting and clinically comforting: once malignant T cells drive a patient to a donor transplant, whether they first declared themselves in the marrow or in the lymph nodes may matter far less than doctors once assumed.

Subject of Research: Comparative post-transplant outcomes of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Article Title: Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation

Article References: Guo, J., Huang, L., Li, Z., Zhang, A., Li, M., Zhang, L., Wang, L., Li, F., Wang, L., Jing, Y., Bo, J., Liu, D., Dou, L., Gu, Z., & Gao, C. (2026). Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation. Annals of Hematology. https://doi.org/10.1007/s00277-026-07295-4

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07295-4

Keywords: T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, allogeneic stem cell transplantation, overall survival, graft-versus-host disease, measurable residual disease, non-relapse mortality, propensity score matching, hematology, restricted mean survival time, relapse, Annals of Hematology

The research team, drawn from Wenzhou People’s Hospital, the First Affiliated Hospital of Wenzhou Medical University, and Shanghai Tongji Hospital, set out to answer a deceptively simple question: do patients who experience gastrointestinal bleeding during first-line chemotherapy for gastrointestinal diffuse large B-cell lymphoma fare worse than those who do not? The challenge in answering such questions retrospectively is confounding. Patients who bleed may differ systematically from those who do not in age, disease stage, tumor biology, or overall fitness, and any of those differences could explain an apparent survival gap. To address this, the investigators turned to propensity score matching, a statistical technique borrowed from epidemiology that attempts to recreate the balance of a randomized trial using observational data.

The mechanics of the analysis are worth understanding, because they underpin the credibility of the findings. The team assembled a cohort of 79 patients with gastrointestinal diffuse large B-cell lymphoma treated with first-line chemotherapy. Within that group, nine patients developed gastrointestinal bleeding after treatment. Each bleeding patient was matched with two controls who did not bleed, producing a 1:2 matched design. The matching variables were chosen with care: gender, clinical stage, Hans classification, which is a widely used immunohistochemical scheme that stratifies diffuse large B-cell lymphoma into germinal center B-cell-like and activated B-cell-like subtypes, and Eastern Cooperative Oncology Group performance status, a standard measure of a patient’s functional fitness. By balancing these key determinants of outcome across the two groups, the researchers could isolate the effect of bleeding itself with far greater confidence than a crude comparison would allow.

The results were striking. Patients who suffered gastrointestinal bleeding after chemotherapy had significantly worse overall survival, with a P value of 0.006, and significantly worse progression-free survival, with a P value of 0.011. Survival curves, however, only tell part of the story. The researchers also examined how the lymphoma responded to treatment, and here the differences were dramatic. The complete response rate, which reflects the proportion of patients whose disease vanished entirely on imaging and clinical assessment, was just 11.11 percent in the bleeding group compared with 66.67 percent in the matched controls, a difference that reached statistical significance at P equals 0.013. The objective response rate, which combines complete and partial responses, was 66.67 percent among bleeders versus 100.00 percent among controls, with a P value of 0.029. In other words, patients who bled were far less likely to achieve a deep remission, and none of the matched controls escaped treatment without at least a partial response.

Perhaps the most forward-looking element of the study is its use of metabolic imaging to predict who will bleed. All of the patients in the cohort underwent baseline fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography, the workhorse of modern lymphoma staging. This technique exploits the fact that rapidly dividing cancer cells consume glucose voraciously; the radioactive glucose analog accumulates in tumor tissue, allowing clinicians to measure not just where disease sits but how metabolically active it is. The researchers focused on parameters specific to the gastrointestinal involvement: the gastrointestinal metabolic tumor volume, abbreviated GI-MTV, which quantifies the physical volume of metabolically active tumor in the gut, and the gastrointestinal total lesion glycolysis, or GI-TLG, which integrates tumor volume with glucose uptake intensity to estimate the total metabolic burden carried by the intestinal disease.

Both parameters proved predictive. Patients who went on to bleed had significantly higher baseline GI-MTV, with a P value of 0.002, and significantly higher GI-TLG, with a P value of 0.004. The biological interpretation is intuitive: bulky, metabolically ravenous tumors in the gastrointestinal wall inflict more local destruction, erode deeper into the mucosa and muscularis layers, and leave behind larger ulcerated craters when chemotherapy begins to kill the malignant cells. When that necrotic tissue sloughs away, exposed blood vessels in the gut wall can hemorrhage. The finding suggests that a routine pre-treatment PET/CT scan, which nearly every lymphoma patient already receives, contains actionable information about bleeding risk that has largely gone unexploited.

The survival analysis within the matched cohort added further texture. High Eastern Cooperative Oncology Group performance status, indicating a patient with significant functional impairment, was associated with poorer overall survival at P equals 0.032 and poorer progression-free survival at P equals 0.008. Whole-body metabolic tumor volume, or Wb-MTV, and total lesion glycolysis, or Wb-TLG, which capture the entire systemic tumor burden rather than just the gastrointestinal component, were each linked to worse overall survival, at P equals 0.012 and P equals 0.038 respectively. The international prognostic index, a composite clinical score incorporating age, stage, performance status, serum lactate dehydrogenase, and the number of extranodal disease sites, was associated with poorer progression-free survival at P equals 0.027. Together, these findings paint a coherent picture in which both the global burden of disease and the patient’s physiological reserve shape outcomes, with bleeding acting as a clinical marker of tumors that were already the most formidable.

One of the more reassuring aspects of the study concerns management. Gastrointestinal bleeding in this setting sounds catastrophic, and it can be, but the majority of events were handled without invasive intervention. Conservative medical therapy, which typically includes acid suppression, bowel rest, transfusion support, and careful monitoring, succeeded in 77.78 percent of the bleeding cases. The remaining 22.22 percent required endoscopic hemostasis, in which a flexible camera is passed into the digestive tract and bleeding vessels are cauterized, clipped, or injected with vasoconstrictive agents. None of the reported events in the matched analysis apparently demanded emergency surgery in the data presented, which is notable given that perforation and hemorrhage in the gut have historically been among the most feared complications of treating gastrointestinal lymphoma. The message for clinicians is twofold: vigilance is essential, but a calibrated, stepwise response beginning with medical management is often sufficient.

The broader significance of this work lies in how it reframes a familiar complication. Gastrointestinal bleeding after chemotherapy has long been treated as an unpredictable accident, a bolt from the blue that clinicians could only react to. This study suggests otherwise. The bleeding events clustered among patients with high metabolic tumor burden in the gut, and those patients also had the worst responses to therapy and the shortest survival. Bleeding, in this framing, is less a random event than a clinical manifestation of aggressive, bulky disease that chemotherapy is struggling to control. That reframing has practical consequences. Patients with high baseline GI-MTV and GI-TLG could be flagged for intensified surveillance during the first treatment cycles, with a low threshold for endoscopic evaluation if any sign of bleeding emerges. They might also be candidates for closer monitoring of hemoglobin and fecal occult blood, or for prophylactic gastroprotective strategies, though the study does not test such interventions directly.

Cautions remain. The study is retrospective and small, with only nine bleeding patients, and propensity score matching can only balance the confounders that are measured and included; unmeasured differences in tumor location, depth of invasion, or treatment details could still contribute. The researchers appropriately note that the work was approved by the ethics committee of the First Affiliated Hospital of Wenzhou Medical University and conducted under the principles of the Helsinki Declaration, with informed consent waived for the retrospective design but patient privacy protected. The research was supported by the Zhejiang Provincial Natural Science Foundation of China. Even with those limitations, the convergence of evidence is compelling: worse survival, worse response rates, and higher baseline metabolic burden all point in the same direction. For a disease that affects the digestive tract of thousands of patients worldwide each year, the ability to look at a pre-treatment PET/CT scan and identify who is most likely to bleed, and to understand that bleeding marks a population in need of heightened attention, represents a meaningful step toward safer and more personalized lymphoma care. The study is published open access, allowing clinicians everywhere to examine the data in full.

Subject of Research: Gastrointestinal bleeding as a prognostic factor after first-line chemotherapy in gastrointestinal diffuse large B-cell lymphoma

Article Title: Outcomes of gastrointestinal bleeding events after first-line chemotherapy in gastrointestinal-diffuse large B-cell lymphoma: a propensity-score matched analysis

Article References: Li, H., Shen, Y., Jia, S., Xu, F., Xue, B., & Ye, H. (2026). Outcomes of gastrointestinal bleeding events after first-line chemotherapy in gastrointestinal-diffuse large B-cell lymphoma: a propensity-score matched analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07272-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07272-x

Keywords: diffuse large B-cell lymphoma, gastrointestinal bleeding, chemotherapy, PET/CT, metabolic tumor volume, propensity score matching, prognosis, overall survival, progression-free survival, endoscopic hemostasis, Annals of Hematology, hematology